Literature DB >> 21393455

Linezolid combined with trimethoprim-sulfamethoxazole therapy for the treatment of disseminated nocardiosis.

Qian Shen1, Hua Zhou1, Heng Li2, Jianying Zhou1.   

Abstract

We describe a case of disseminated nocardiosis in a 45-year-old male with a history of chronic glomerular nephritis and allograft renal transplantation both treated with immunosuppressive drugs. Clinical symptoms included fever, chest distress, breathlessness, subcutaneous nodules and pustules. Pulmonary computed tomography scans revealed areas of consolidation in both lung fields, pleural effusion and massive pericardial effusion. Bacterial culture of the pus in the subcutaneous abscesses and pericardial effusion showed growth of Nocardia asteroides sensitive to linezolid and trimethoprim-sulfamethoxazole (TMP-SMZ) for both. Treatment with linezolid combined with TMP-SMZ resulted in a clear clinical improvement and bacterial clearance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393455     DOI: 10.1099/jmm.0.018549-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  3 in total

1.  Successful treatment of disseminated nocardiosis diagnosed by metagenomic next-generation sequencing: A case report and review of literature.

Authors:  Ting Li; Yi-Xin Chen; Jia-Jia Lin; Wei-Xian Lin; Wei-Zhen Zhang; Hang-Ming Dong; Shao-Xi Cai; Ying Meng
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

2.  First Report of Nocardia asiatica Presenting as an Anterior Mediastinal Mass in a Patient with Myasthenia Gravis: A Case Report and Review of the Literature.

Authors:  Rima I El-Herte; Souha S Kanj; George F Araj; Hassan Chami; Walid Gharzuddine
Journal:  Case Rep Infect Dis       Date:  2012-07-16

3.  Clinical findings of 40 patients with nocardiosis: A retrospective analysis in a tertiary hospital.

Authors:  Meifang Yang; Min Xu; Wei Wei; Hainv Gao; Xuan Zhang; Hong Zhao; Jianhua Hu; Huihui Dong; Lichen Xu; Lanjuan Li
Journal:  Exp Ther Med       Date:  2014-05-14       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.